APA (7th ed.) Citation

LA, K. F., S, C., MB, S., PM, K., JS, S., AJ, L., . . . HH, Y. (2021). Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. International journal of cancer, 149(2), 378. https://doi.org/10.1002/ijc.33559

Chicago Style (17th ed.) Citation

LA, Kankeu Fonkoua, et al. "Outcomes on Anti-VEGFR-2/paclitaxel Treatment After Progression on Immune Checkpoint Inhibition in Patients with Metastatic Gastroesophageal Adenocarcinoma." International Journal of Cancer 149, no. 2 (2021): 378. https://doi.org/10.1002/ijc.33559.

MLA (9th ed.) Citation

LA, Kankeu Fonkoua, et al. "Outcomes on Anti-VEGFR-2/paclitaxel Treatment After Progression on Immune Checkpoint Inhibition in Patients with Metastatic Gastroesophageal Adenocarcinoma." International Journal of Cancer, vol. 149, no. 2, 2021, p. 378, https://doi.org/10.1002/ijc.33559.